AU5568396A - Methods of screening for therapeutic agents using novel apop tosis-modulating proteins - Google Patents

Methods of screening for therapeutic agents using novel apop tosis-modulating proteins

Info

Publication number
AU5568396A
AU5568396A AU55683/96A AU5568396A AU5568396A AU 5568396 A AU5568396 A AU 5568396A AU 55683/96 A AU55683/96 A AU 55683/96A AU 5568396 A AU5568396 A AU 5568396A AU 5568396 A AU5568396 A AU 5568396A
Authority
AU
Australia
Prior art keywords
screening
novel
methods
therapeutic agents
modulating proteins
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU55683/96A
Inventor
Philip J. Barr
Michael C Kiefer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
LXR Biotechnology Inc
Original Assignee
LXR Biotechnology Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by LXR Biotechnology Inc filed Critical LXR Biotechnology Inc
Publication of AU5568396A publication Critical patent/AU5568396A/en
Abandoned legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6845—Methods of identifying protein-protein interactions in protein mixtures
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4747—Apoptosis related proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Food Science & Technology (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU55683/96A 1995-04-20 1996-04-19 Methods of screening for therapeutic agents using novel apop tosis-modulating proteins Abandoned AU5568396A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US42652995A 1995-04-20 1995-04-20
US426529 1995-04-20
PCT/US1996/005639 WO1996033416A1 (en) 1995-04-20 1996-04-19 Methods of screening for therapeutic agents using novel apoptosis-modulating proteins

Publications (1)

Publication Number Publication Date
AU5568396A true AU5568396A (en) 1996-11-07

Family

ID=23691171

Family Applications (1)

Application Number Title Priority Date Filing Date
AU55683/96A Abandoned AU5568396A (en) 1995-04-20 1996-04-19 Methods of screening for therapeutic agents using novel apop tosis-modulating proteins

Country Status (5)

Country Link
EP (1) EP0821793A1 (en)
JP (1) JP3615552B2 (en)
AU (1) AU5568396A (en)
CA (1) CA2216856C (en)
WO (1) WO1996033416A1 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995015084A1 (en) * 1993-11-30 1995-06-08 Lxr Biotechnology Inc. Novel apoptosis-modulating proteins, dna encoding the proteins and methods of use thereof
AU6679498A (en) 1997-03-20 1998-10-12 Lxr Biotechnology Inc. A novel bak binding protein, dna encoding the protein, and methods of use thereof
US6344330B1 (en) * 1998-03-27 2002-02-05 The Regents Of The University Of California Pharmacophore recombination for the identification of small molecule drug lead compounds
EP1370678A4 (en) * 2001-03-02 2005-09-07 Mds Proteomics Inc Methods and reagents for regulating apoptosis

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995005738A1 (en) * 1993-08-20 1995-03-02 Massachusetts Institute Of Technology Anticancer agents and apoptosis
US5700638A (en) * 1993-08-26 1997-12-23 Washington University Cell death regulator
WO1995015084A1 (en) * 1993-11-30 1995-06-08 Lxr Biotechnology Inc. Novel apoptosis-modulating proteins, dna encoding the proteins and methods of use thereof

Also Published As

Publication number Publication date
JPH11504423A (en) 1999-04-20
CA2216856A1 (en) 1996-10-24
CA2216856C (en) 2008-02-19
WO1996033416A1 (en) 1996-10-24
EP0821793A1 (en) 1998-02-04
JP3615552B2 (en) 2005-02-02

Similar Documents

Publication Publication Date Title
AU5893696A (en) Modification of polypeptides
HUP9900422A3 (en) Novel protein and methods for the production of the same
AU5268696A (en) Novel compounds and methods for therapy
AU7566396A (en) Process for the preparation of peptides by way of streptavidin fusion proteins
AU6916296A (en) Recombinant anti-cd4 antibodies for human therapy
EP0637630A3 (en) Method for the biological synthesis of peptides
AU5445296A (en) Methods for preparing dna-binding proteins
EP0846265A4 (en) Methods for g protein coupled receptor activity screening
AU7317496A (en) Activation of p53 protein
AU5893796A (en) Modification of polypeptides
AU4930993A (en) Coupled replication-translation methods and kits for protein synthesis
AU3549397A (en) Over-expression of proteins
AU4207196A (en) Method of improving quality of eggs
AU6489996A (en) Methods for increasing protein expression
AU6517396A (en) Preparation of N-substituted 3-hydroxypyrazoles
AU6873596A (en) Allergen-xcd32 fusion proteins
AU8059391A (en) Method of making peptides
PL321239A1 (en) Mutations of proteins
HUP9601261A3 (en) Process for preparation of 2-fluor-pirimidine-derivatives
AU5568396A (en) Methods of screening for therapeutic agents using novel apop tosis-modulating proteins
AU7520396A (en) Abl-interactor protein
AU5486396A (en) Process for the preparation of spiroindolines
AU7096496A (en) Process for the preparation of 4-methylenepiperidines
AU5284296A (en) Immune-evading proteins
AU7146698A (en) Method of determining three-dimensional protein structure from primary protein sequence